Evidence map›Paper›PMID 23933760›Full record

ArticleBone marrow transplantation2014

Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL.

M Eefting, C J M Halkes, L C de Wreede, C M van Pelt, S Kersting, E W A Marijt, P A von dem Borne, R Willemze, H Veelken, J H F Falkenburg

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Graft versus tumor effects and why people relapse.Hematology. American Society of Hematology. Education Program · 2017
    Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

10 authors.

M EeftingDepartment of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
C J M HalkesDepartment of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
L C de WreedeDepartment of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, The Netherlands.
C M van PeltDepartment of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
S KerstingDepartment of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
E W A MarijtDepartment of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
P A von dem BorneDepartment of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
R WillemzeDepartment of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
H VeelkenDepartment of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
J H F FalkenburgDepartment of Hematology, Leiden University Medical Center, Leiden, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prognosis of adult patients with ALL remains unsatisfactory. AlloSCT is associated with a beneficial GVL response mediated by donor T cells. However, GVHD results in substantial mortality and long-term morbidity. T-cell depletion (TCD) of the graft reduces the severity of GVHD, but is associated with an increased relapse rate after alloSCT. Therefore, early sequential donor lymphocyte infusion (DLI) is likely to be necessary for a successful GVL reaction. Twenty-five adult ALL patients (10 Ph(+)ALL) were eligible for early DLI after initial disease control with myeloablative TCD-alloSCT in first CR (CR1), if active GVHD was absent at 3-6 months after alloSCT. Patients with a sibling donor or an unrelated donor were scheduled for 3.0 × 10(6) CD3(+) cells/kg or 1.5 × 10(6) CD3(+) cells/kg, respectively, at 6 months after alloSCT. Three patients died before evaluation (one early relapse). Five patients had active GVHD. Fourteen of the remaining seventeen patients received DLI (median time-to-DLI: 185 days). Overall, only 17% required long-term systemic immunosuppression for GVHD. With a median follow-up after TCD-alloSCT of 50 months, 2-year survival probability was 68% (95% confidence interval (CI) 49-87%). In conclusion, myeloablative TCD-alloSCT with early sequential DLI is an efficient and safe post-remission treatment for adult ALL patients in CR1.

Indexed as

AdultFemaleHematopoietic Stem Cell TransplantationHumansLymphocyte DepletionLymphocyte TransfusionMaleMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaPrognosisTissue DonorsT-LymphocytesTransplantation ConditioningTransplantation, HomologousYoung Adult

Identifiers

PMID23933760

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.